Henri's methicilani capsules and Malay acid pyridinist tablets were approved for clinical trials.

Introduction: Henrui pharmaceutical injection with Karelli pearl monoanti, nectic acid famini capsule combined chemotherapy approved clinical, innovative drug Malay acid pyrithione new adaptation was approved clinically.
. On September 14, Hengrui Pharmaceuticals announced that the company and its subsidiary, Shanghai Hengrui Pharmaceutical Co., Ltd., had recently received a "Notice of Approval for Clinical Trials of Drugs" issued by the State Drug Administration regarding the magnate methini capsules and Malay acid pyridoxine tablets, and that clinical trials would be conducted in the near future.
(i) Mercidini capsules specifically as follows: injection with carelli bead monoantigeno combined with meritini capsules or placebos with Pometroser and carpentry first-line treatment of patients with advanced or metastasis non-small cell lung cancer randomized, double-blind, controlled, multi-center III clinical studies (programme number: SHR-1210-III-324).
the company's innovatively developed small molecule multi-target tyrosine kinase inhibitor.
inquiries, apple acid famini at home and abroad at home and abroad have Sorafini, Shoni tinini, Peezopani and other similar products have been approved for listing.
Sorafoni was developed by Bayer and approved for listing in the United States in 2005;
three multi-target inhibitors have been approved for listing in China.
, Solapini, Shonitini and Peropani have global sales of approximately US$2,159 million in 2019.
, the product has invested a cumulative total of about 123.04 million yuan in research and development.
(ii) The approval conclusion of the Malay acid pyridoxine tablets was that: phase II clinical trials of patients with HER2 abnormality of her2 abnormality who had failed first-line chemotherapy.
inquiries, similar products listed abroad are Tykerb®®, Nerlynx ® (tucatinib), Gilotrif® and Vizimpro ® (dacomitinib).
Tykerb® developed by GlaxoSmithKline, was first approved by the U.S. Food and Drug Administration in March 2007 with a specification of 250 mg/piece and has been imported and marketed in China.
Nerlynx ® developed by PumaBiotechnology, Inc., was approved by the U.S. Food and Drug Administration in July 2017 and approved for listing by China's State Drug Administration in May 2020.
Tukysa ® developed by Seattle Genetics and approved by the U.S. Food and Drug Administration in April 2020 at a size of 150 mg/tablet.
, ® developed by Boehringer Iningelheim, was approved for listing by the U.S. Food and Drug Administration in 2013 and has been imported into the market.
Vizimpro ® developed by Pfizer and approved by the U.S. Food and Drug Administration in 2018.
global sales of Tukysa®, Nerlynx®, Tukysa®, Gilotrif® and Vizimpro ® will be approximately $440 million in 2019.
, the product has invested a cumulative total of about 843.63 million yuan in research and development.
.